CIA
SGMO

Capital Impact Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Capital Impact Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,413
Closed -$136K – 222
2016
Q2 		$136K Hold
23,413
– – 0.06% 217
2016
Q1 		$142K Hold
23,413
– – 0.07% 218
2015
Q4 		$214K Hold
23,413
– – 0.1% 247
2015
Q3 		$132K Hold
23,413
– – 0.07% 250
2015
Q2 		$260K Hold
23,413
– – 0.12% 245
2015
Q1 		$367K Buy
+23,413
New +$362K 0.17% 222

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Capital Impact Advisors's SGMO Position: Q3 2016 in Review

Capital Impact Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2016, closing a stake of 23,413 shares — an estimated $136K sold.

Capital Impact Advisors first reported a position in SGMO in Q1 2015 and held it in 6 quarters. The position peaked at $367K in Q1 2015. 124 funds tracked by Wall St. Rank hold SGMO as of Q3 2016.

  • Capital Impact Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2016 after selling out during the quarter.
  • Capital Impact Advisors sold 23,413 SANGAMO THERAPEUTICS INC shares in Q3 2016, an estimated $136K.
  • Capital Impact Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 6 quarters.
  • Capital Impact Advisors's SANGAMO THERAPEUTICS INC position peaked at $367K in Q1 2015.
  • 124 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2016.

Based on Capital Impact Advisors's 13F filing for Q3 2016, filed 6 Oct 2016.